ALX Oncology Announces November Investor Conference Participation
01 November 2023 - 9:05PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that management
will participate in three upcoming investor conferences in
November.
2023 UBS BioPharma ConferenceFormat: Fireside
chat with analyst, Dr. Colin BristowDate: Wednesday, November
8thTime: 1:30 PM ESTLocation: Miami Beach, FLWebcast link:
Available here
2023 Jefferies London Healthcare
ConferenceFormat: Fireside chat with analyst, Michael
YeeDate: Tuesday, November 14th Time: 3:00 PM GMTLocation: London,
UK Webcast link: Available here
2023 Piper Sandler Healthcare ConferenceFormat:
Fireside chat with analyst, Christopher RaymondDate: Tuesday,
November 28th Time: 4:30 PM ESTLocation: New York, NY Webcast
link: Available here
The live webcasts for the UBS, Jefferies and Piper Sandler
fireside chats can be accessed by visiting the Investors section of
ALX Oncology’s website at www.alxoncology.com and
selecting Events under the News and Events tab. A replay
of the webcast will be archived for up to 90 days following the
fireside chat date.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 immune checkpoint
inhibitor and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain.
Evorpacept has demonstrated promising clinical responses across a
range of hematologic and solid malignancies in combination with a
number of leading anti-cancer antibodies. ALX Oncology is currently
focusing on combining evorpacept with anti-cancer antibodies, ADCs,
and PD-1/PD-L1 immune checkpoint inhibitors.
Evorpacept’s Rational Design and Dual Development
Pillars
Rationally engineered with an inactive Fc effector function,
evorpacept’s clinical data to date has demonstrated a substantially
improved safety profile over other anti-CD47 molecules in the
clinic with an active Fc (i.e., binding the Fc gamma receptor on
macrophages). This superior safety profile allows higher dosing
with minimal overlapping toxicity in the combination treatment
setting. CD47 expressed on cancer cells binds to its receptor SIRP
alpha, which is predominantly expressed on two cell types:
macrophages and dendritic cells. ALX Oncology is focusing
evorpacept development with the standard-of-care agents as
originally designed revolving around these two cell types,
including:
Anti-cancer antibodies (the “don’t eat
me” signal): evorpacept enables Fc-mediated
antibody-dependent phagocytosis by macrophages in combination with
anti-cancer antibodies (e.g., Herceptin®) with an active Fc domain,
which is otherwise impaired by CD47 expression on cancer cells
binding to SIRP alpha on macrophages. This same mechanism of action
applies to ADCs.
PD-1/PD-L1 immune checkpoint inhibitors (the
“don’t activate T-cells” signal):
evorpacept enables T-cell activation by dendritic cells that are
constitutively inhibited by CD47 expression on cancer cells binding
to SIRP alpha on dendritic cells. Activated dendritic cells present
neoantigens to T-cells that once activated will kill cancer cells
when the PD-1/PD-L1 inhibitory interaction is blocked by T-cell
checkpoint inhibitors.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
mchatterjee@bplifescience.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024